High-Dose Ifosfamide by Infusion with Mesna in Advanced Refractory Sarcomas

Twenty patients with advanced sarcomas entered a pilot study with ifosfamide (IF) and mercaptoethane sulfonate sodium (Mesna) as a second-line treatment for six planned cycles. All patients had received prior doxorubicin- and cyclophosphamide-based chemotherapies. IF was administered at a dose of 3...

Ausführliche Beschreibung